Shares of Nasus Pharma Ltd. (AMEX:NSRX) experienced a significant decline on Monday, dropping to a new 52-week low of $2.82. This sharp decrease followed the announcement of topline results from a Phase 2 study of NS002, an investigational intranasal epinephrine powder formulation aimed at treating anaphylaxis, a severe allergic reaction.
Despite an initial surge in share price to $7.29 after the study results were released during the premarket session, the stock quickly fell. The Phase 2 trial demonstrated that NS002 has the potential to outperform the widely used EpiPen in several key metrics.
Promising Results and Fast Performance
The Phase 2 study revealed statistically significant improvements in the time it takes for patients to reach the therapeutic epinephrine threshold, known as T100. NS002 achieved a median T100 of 1.69 minutes, compared to 3.42 minutes for EpiPen. By the ten-minute mark, approximately 95% of participants who received NS002 reached the necessary therapeutic threshold.
At the five-minute interval, 88.4% of those administered NS002 met the threshold, whereas only 64.6% of EpiPen users did. Notably, NS002 demonstrated a favorable safety profile, with no serious adverse events reported throughout the study.
Earlier interim data released in January indicated that 91% of participants administered NS002 reached the epinephrine plasma threshold of 100 pg/ml at the five-minute mark, compared to only 67% for those using EpiPen. Furthermore, NS002 displayed a higher mean peak plasma concentration (Cmax) of 655 pg/ml versus 548 pg/ml for EpiPen and achieved peak concentration (Tmax) in 10.8 minutes compared to 15 minutes for EpiPen. The latest data showed a median Tmax of 15 minutes for NS002 against 19.8 minutes for EpiPen.
Future Development Plans
The study involved 50 healthy adults with a history of allergic rhinitis, and participants received both NS002 and intramuscular EpiPen doses. The results indicate that NS002’s pharmacodynamic response is comparable to EpiPen across all participants, reinforcing its potential as a leading product in anaphylaxis treatment.
Looking ahead, the company plans to initiate a pivotal study in the fourth quarter of 2026, which could further validate NS002’s efficacy and market potential. While the recent study results are promising, the market’s reaction has nevertheless led to a notable decline in share value.
As of Monday’s publication, the stock price reflects a 43.60% drop from previous levels, raising concerns among investors about the future trajectory of Nasus Pharma. According to data from Benzinga Pro, the stock is now trading at a new 52-week low.
Investors and analysts will be watching closely as the company moves forward with its development plans and prepares for the next phase of clinical trials.